Nektar Therapeutics
Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
| Formerly | Inhale Therapeutic Systems, Inc. |
|---|---|
| Company type | Public company |
| Industry | Biopharmaceuticals |
| Founded | 1990 |
| Headquarters | San Francisco, California, U.S. |
| Products | |
| Revenue | US$1.13 billion (2018) |
Number of employees | 718 (2020) |
| Website | nektar |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.